Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema

NCT07654829 is registered in ClinicalTrials.gov with KalVista Pharmaceuticals, Ltd. as lead sponsor.

NCT NCT07654829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07654829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Open-Label Trial to Evaluate the Safety and Effectiveness of Sebetralstat When Used as Preprocedural Short-term Prophylaxis in Patients With Hereditary Angioedema
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Phase
Phase 4
Overall status
Recruiting
Start date
August 17, 2026
Completion date
December 6, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary angioedema